Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELDN Eledon Pharmaceuticals, Inc.

Closed 05-27 16:00:00 EDT

3.90

+0.01

+0.26%

盘后3.93

+0.03+0.77%

19:59 EDT

High3.97	Low3.82	Vol963.64K
Open3.86	D1 Closing3.89	Amplitude3.84%
Mkt Cap301.03M	Tradable Cap267.47M	Total Shares77.19M
T/O3.75M	T/O Rate1.41%	Tradable Shares68.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ELDN","market":"US","secType":"STK","nameCN":"Eledon Pharmaceuticals, Inc.","latestPrice":3.9,"timestamp":1779912000000,"preClose":3.89,"halted":0,"volume":963636,"hourTrading":{"tag":"盘后","latestPrice":3.93,"preClose":3.9,"latestTime":"19:59 EDT","volume":9565,"amount":37305.4464775,"timestamp":1779926388345,"change":0.03,"changeRate":0.007692,"amplitude":0.021359},"delay":0,"changeRate":0.002570694087403544,"floatShares":68583200,"shares":77187800,"eps":-0.860885,"marketStatus":"Closed","change":0.01,"latestTime":"05-27 16:00:00 EDT","open":3.86,"high":3.9695,"low":3.82,"amount":3753081.0310152,"amplitude":0.038432,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.860885,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779955200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":3.89,"preHourTrading":{"tag":"盘前","latestPrice":3.9,"preClose":3.89,"latestTime":"09:19 EDT","volume":1449,"amount":5602.2988392,"timestamp":1779887967842,"change":0.01,"changeRate":0.002571,"amplitude":0.026093},"postHourTrading":{"tag":"盘后","latestPrice":3.93,"preClose":3.9,"latestTime":"19:59 EDT","volume":9565,"amount":37305.4464775,"timestamp":1779926388345,"change":0.03,"changeRate":0.007692,"amplitude":0.021359},"volumeRatio":1.002653,"impliedVol":1.8989,"impliedVolPercentile":0.7131},"requestUrl":"/m/hq/s/ELDN","defaultTab":"news","newsList":[{"id":"2637022317","title":"Analysts Offer Insights on Healthcare Companies: Whitehawk Therapeutics (WHWK) and Eledon Pharmaceuticals (ELDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637022317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637022317?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:00","pubTimestamp":1779458442,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Whitehawk Therapeutics (WHWK) and Eledon Pharmaceuti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-whitehawk-therapeutics-whwk-and-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-whitehawk-therapeutics-whwk-and-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XLV","HCSG","BK4139","BK4585","XBI","LU0128526141.USD","ELDN","LABU","WHWK","BK4137","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878548","title":"Eledon presents new long-term Phase 2 BESTOW kidney transplant data for tegoprubart at ATC","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878548","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637878548?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:06","pubTimestamp":1779307599,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals scheduled new long-term data from its Phase 2 BESTOW kidney transplant program for presentation at the American Transplant Congress in Boston on June 20-24, 2026.The update will cover longer follow-up from tegoprubart studies aimed at preventing kidney transplant rejection, with a focus on safety and efficacy outcomes.An oral presentation is set for June 22, 2026, with an accompanying conference call the same morning to discuss the updated BESTOW results and extension-study findings.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL6VFXFf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4588","SG9999014005.SGD","ELDN","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","BK4112","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","BK4139","SG9999014021.USD","LU0314104364.USD","BK4585","NDAQ","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079424","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079424","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079424?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:30","pubTimestamp":1779111014,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eledon Pharmaceuticals (ELDN), Neurocrine (NBIX) and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-177?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-177?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0154245756.USD","XBI","LU2065170008.USD","LU2065169927.USD","LU0320765992.SGD","NBIX","LU0889565916.HKD","LU2065171311.SGD","BLSG","BK4588","BLSX","LABU","LU0154245673.USD","BK4139","LU0029874061.USD","LU0823416689.USD","BK4585","BK4112","LU0128526141.USD","BK4581","ELDN","LU2324357040.USD","LU2065171402.SGD","LU0109394709.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635811717","title":"LifeSci Capital Remains a Buy on Eledon Pharmaceuticals (ELDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635811717","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635811717?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:17","pubTimestamp":1778761029,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Eledon Pharmaceuticals today and set a price target of $6.00. Katkhuda covers the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635751332","title":"BRIEF-Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results And Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635751332","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635751332?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:55","pubTimestamp":1778709302,"startTime":"0","endTime":"0","summary":"BRIEF-Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results And Recent Business HighlightsMay 13 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O:ELEDON PHARMACEUTICALS REPORTS FIRST QUARTE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA4MV7Q1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635759170","title":"Eledon Pharma Q1 EPS $(0.33) Misses $(0.18) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635759170","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635759170?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:32","pubTimestamp":1778707974,"startTime":"0","endTime":"0","summary":"Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 312.5 percent decrease over losses of $(0.08) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52547314/eledon-pharma-q1-eps-0-33-misses-0-18-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Eledon Pharma Q1 EPS $(0.33) Misses $(0.18) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635580759","title":"Eledon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635580759","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635580759?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:18","pubTimestamp":1778707089,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryEledon Pharmaceuticals Inc ELDN.OQ reported a quarterly adjusted loss of 33 cents per share for the quart","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q2WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753457","title":"Eledon Pharmaceuticals Q1 net loss widens on warrant liability loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753457","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753457?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:21","pubTimestamp":1778703660,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Q1 net loss widens on warrant liability lossOverviewUS biotech firm's Q1 net loss widened yr/yr, impacted by non-cash warrant liability lossCompany highlighted positive tegoprub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q16J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753576","title":"Eledon Q1 FY26 net loss widens to $39.03 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753576?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:12","pubTimestamp":1778703120,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals posted a Q1 net loss of USD 39 million, or USD 0.33 per share, versus a net loss of USD 6.5 million, or USD 0.08 per share, a year earlier.Operating loss widened to USD 21.18 million as R&D expense climbed to USD 17.2 million from USD 13.5 million.Cash, cash equivalents, short-term investments fell to USD 111.1 million as of March 31 from USD 133.3 million at end-2025; runway seen into 2Q 2027.Non-cash loss from warrant liability fair-value changes was USD 19 million; excluding those items, net loss was USD 20.1 million.Reported 100% insulin independence in 10 islet-transplant patients treated with tegoprubart, received FDA orphan-drug designation in liver transplantation, and expects FDA guidance in 2026 to support Phase 3 planning in kidney transplantation.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL6fdhS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","BK4585","BK4139","ELDN","IE00B64PRP62.GBP","SG9999014039.USD","BK4588","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014013.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758413","title":"Eledon Pharmaceuticals Q1 Net Income USD -39.025 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758413","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758413?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702703,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXCBDDBB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635756203","title":"Eledon Pharmaceuticals Q1 Basic EPS USD -0.33","url":"https://stock-news.laohu8.com/highlight/detail?id=2635756203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635756203?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702703,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXCBDDBB:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753870","title":"Press Release: Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753870","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753870?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702700,"startTime":"0","endTime":"0","summary":"100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study. FDA Orphan Drug designation granted to tegoprubart for the prevention of allograft rejection in liver transplantation. Cash, cash equivalents and short-term investments totaled $111.1 million as of March 31, 2026. \"In the first quarter of 2026, we achieved significant milestones in our tegoprubart program, including important data updates in kidney and islet cell transplantation and FDA Orphan Drug designation for tegoprubart in liver transplantation,\" said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. \"Looking ahead, we expect multiple catalysts in 2026, including regulatory engagements supporting the advancement of tegoprubart into Phase 3 development in kidney transplantation and discussions regarding a potential path to market in islet cell transplantation. We also plan to initiate several new clinical tr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633543455","title":"Eledon Pharmaceuticals Inc  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633543455","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633543455?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:58","pubTimestamp":1778241487,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Inc  expected to post a loss of18cents a share - Earnings Preview Eledon Pharmaceuticals Inc ELDN.OQ ELDN.O is expected to  show no change in quarterly revenue when it reports  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L17A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647049","title":"Eledon Pharmaceuticals Files $500 Million Mixed Shelf Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647049","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647049?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:32","pubTimestamp":1777667534,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals  filed a registration statement late Friday for the potential sale of up to $500 million of securities from time to time.The filing covers common and preferred stock, debt securities, warrants and units.Net proceeds will be used for general corporate purposes, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647934","title":"Eledon Pharmaceuticals files $500M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647934","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647934?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:15","pubTimestamp":1777666519,"startTime":"0","endTime":"0","summary":"16:10 EDT Eledon Pharmaceuticals (ELDN) files $500M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eledon-pharmaceuticals-files-500m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eledon-pharmaceuticals-files-500m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631634773","title":"Newcelx Reports Financial Results for 2025 and Provides Shareholders With Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration With Eledon Pharmaceuticals in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631634773","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631634773?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:15","pubTimestamp":1777551300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA4KWLWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELDN","BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631348286","title":"EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2631348286","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631348286?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:01","pubTimestamp":1777550469,"startTime":"0","endTime":"0","summary":"NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/04/52166830/exclusive-newcelx-eyes-accelerated-2026-execution-for-diabetes-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL","ELDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629082759","title":"Eledon Pharmaceuticals announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629082759","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629082759?lang=en_us&edition=fundamental","pubTime":"2026-04-21 18:01","pubTimestamp":1776765710,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals scheduled annual stockholders meeting for June 18, 2026 in Irvine, California.Shareholders to vote on election of Class III directors David-Alexandre C. Gros, Jan Hillson, James Robinson to terms ending at 2029 annual meeting.Ballot includes charter amendment to raise authorized common stock to 450,000,000 shares from 300,000,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL998MB8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELDN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628474697","title":"NewcelX publishes updated corporate presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2628474697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628474697?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:37","pubTimestamp":1776685072,"startTime":"0","endTime":"0","summary":"NewcelX published updated corporate presentation highlighting Type 1 Diabetes flagship program NCEL-101.Presentation includes strategic collaboration with Eledon integrating NewcelX stem-cell-derived islet replacement platform with Eledon anti-CD40L monoclonal antibody tegoprubart.Update frames combined approach as strategy to support durable graft survival for Type 1 Diabetes.Management plans to present updated materials at Swiss Biotech Conference.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLbTDVY4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","NCEL","SG9999014039.USD","BK4588","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","SG9999014005.SGD","IE00BKPKM429.USD","ELDN","LU0314104364.USD","SG9999014013.SGD","BK4112","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621066972","title":"Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621066972","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621066972?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:17","pubTimestamp":1774347453,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eldn/eledon-pharmaceuticals/news/is-eledon-pharmaceuticals-nasdaqeldn-in-a-good-position-to-d-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eldn/eledon-pharmaceuticals/news/is-eledon-pharmaceuticals-nasdaqeldn-in-a-good-position-to-d-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSQ","TSYW.SI","QQQJ","QYLG","NVIW.SI","MNQmain",".IXIC","QLD","QQQE","QID","GPIQ","BK4139","ELDN","SQQQ","JEPQ","USJW.SI","NQmain","TQQQ","QQQY","USAW.SI"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.eledon.com","stockEarnings":[{"period":"1week","weight":0.0866},{"period":"1month","weight":0.1227},{"period":"3month","weight":0.5749},{"period":"6month","weight":1.5097},{"period":"1year","weight":0.2754},{"period":"ytd","weight":1.5762}],"compareEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.0513},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1043},{"period":"1year","weight":0.2961},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.166113},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.000872},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.044379},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009056},{"month":5,"riseRate":0.583333,"avgChangeRate":0.74988},{"month":6,"riseRate":0.181818,"avgChangeRate":-0.182936},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.081289},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.035259},{"month":9,"riseRate":0.272727,"avgChangeRate":0.085532},{"month":10,"riseRate":0.5,"avgChangeRate":2.263696},{"month":11,"riseRate":0.5,"avgChangeRate":-0.069266},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.094259}],"exchange":"NASDAQ","name":"Eledon Pharmaceuticals, Inc.","nameEN":"Eledon Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eledon Pharmaceuticals, Inc.(ELDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eledon Pharmaceuticals, Inc.,ELDN,Eledon Pharmaceuticals, Inc.股票,Eledon Pharmaceuticals, Inc.股票老虎,Eledon Pharmaceuticals, Inc.股票老虎国际,Eledon Pharmaceuticals, Inc.行情,Eledon Pharmaceuticals, Inc.股票行情,Eledon Pharmaceuticals, Inc.股价,Eledon Pharmaceuticals, Inc.股市,Eledon Pharmaceuticals, Inc.股票价格,Eledon Pharmaceuticals, Inc.股票交易,Eledon Pharmaceuticals, Inc.股票购买,Eledon Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eledon Pharmaceuticals, Inc.(ELDN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eledon Pharmaceuticals, Inc.(ELDN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction